SandboxAlonso: Difference between revisions
Jump to navigation
Jump to search
| Line 7: | Line 7: | ||
{{familytree | | | |,|-|^|-|.| | | |}} | {{familytree | | | |,|-|^|-|.| | | |}} | ||
{{familytree | | | C01 | | C02 | | | C01=Local or regional recurrence|C02=Systemic [[metastasis]]}} | {{familytree | | | C01 | | C02 | | | C01=Local or regional recurrence|C02=Systemic [[metastasis]]}} | ||
{{familytree/end}} | {{familytree/end}} | ||
Revision as of 15:57, 24 June 2014
Follow-up
| Controls of history + physical exam and chest CT with or without contrast every 6-12 months (first 2 years), then annual controls | |||||||||||||||||||||||||
| Is there evidence of local or regional recurrence OR systemic metastasis? | |||||||||||||||||||||||||
| Local or regional recurrence | Systemic metastasis | ||||||||||||||||||||||||
Third line therapy
The algorithm below shows the third line therapy for metastatic disease according to the 2014 NCCN Non-Small Cell Lung Cancer guidelines.
| What is the performance status of the patient? | |||||||||||||||||||||||||||||||
| PS 0-2 | PS 3-4 | ||||||||||||||||||||||||||||||
If not previously used, administer any of the following:
| Administer erlotinib or provide suportive care | ||||||||||||||||||||||||||||||
| What is the performance status of the patients after the treatment? | |||||||||||||||||||||||||||||||
| PS 0-2 (stable tumor) | PS 3-4 (tumor progression) | ||||||||||||||||||||||||||||||
| Provide supportive care or try experimental treatments | Provide supportive care | ||||||||||||||||||||||||||||||
Chemotherapy followed by radiotherapy
The list bellow show the options for chemotherapy followed by radiation therapy based on the 2014 NCCN Non-Small Cell Lung Cancer guidelines.[1]
- Cisplatin 100 mg/m2 on days 1 and 29 + vinblastin 5 mg/m2 per week on days 1, 8, 15, 22 and 29, then followed by radiation therapy.
- Paclitaxel 200 mg/m2 administered for 3 hours in the first day + carboplatin AUC 6 administered in 1 hour and then every 21 days to a total of 2 cycles followed by thoracic radiation therapy.
Chemotherapy plus radiotherapy, followed by chemotherapy
The list bellow show the options for concomitant chemotherapy plus radiation therapy followed by chemotherapy based on the 2014 NCCN Non-Small Cell Lung Cancer guidelines.[1]
- Cisplatin 50 mg/m2 on days 1, 8, 29 and 36 + etoposide 50 mg/m2 through day 1 to 5 and then 29 to 33 + thoracic radiation therapy, then followed by cisplatin 50 mg/m2 + etoposide 50 mg/m2 to a total of 2 cycles.
- Paclitaxel 45 to 50 mg/m2 once a week + carboplatin AUC 2 + thoracic radiation therapy, then followed by Paclitaxel 200 mg/m2 + carboplatin AUC 6 to a total of 2 cycles.
Palliative Radiation Therapy Regimens
Listed bellow are the recommended palliative radiation therapy regimens for patients with non-small cell lung cancer according to the 2014 NCCN Non-Small Cell Lung Cancer guidelines[1]
- Obstructive disease: Administer fractions of 3 Gy over a period of 2 to 3 weeks to a total dose of 30 to 45 Gy.
- Bone metastases associated with soft tissue mass: Administer fractions of 4 to 3 Gy over a period of 1 to 2 weeks to a total dose of 20 to 30 Gy.
- Bone metastases not associated with soft tissue mass: Administer fractions of 8 to 3 Gy over a period of 1 to 14 days to a total dose of 8 to 30 Gy.
- Patients with poor performance status and symptomatic chest disease: Administer fractions of 8.5 Gy over a period of 7 to 14 days to a total dose of 17 Gy.
- Metastatic disease in patients who have a poor performance status: Administer fractions of 8 to 4 Gy over a period of 1 to 7 days to a total dose of 8 to 20 Gy.
- Whole brain radiation therapy regimens for metastases to the brain are the following Adapted from the 2014 NCCN Central Nervous System Cancers guidelines[2]:
- 10 fractions of 3 Gy each to a total of 30 Gy.
- 15 fractions of 2.5 Gy each to a total of 37.5 Gy.
- 5 fractions of 4 Gy each to a total of 20 Gy. Good option for patients with poor performance status.